Verma, M., Obergfell, K., Topp, S., Panier, V., & Wu, J. (2023). The next-generation CAR-T therapy landscape. Nature Reviews. Drug Discovery, 22(10), 776–777. https://doi.org/10.1038/d41573-023-00140-7

Article  PubMed  CAS  Google Scholar 

Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015). CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 125(26), 4017–4023. https://doi.org/10.1182/blood-2014-12-580068

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507–1517. https://doi.org/10.1056/NEJMoa1407222

Article  PubMed  CAS  Google Scholar 

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439–448. https://doi.org/10.1056/NEJMoa1709866

Article  PubMed  CAS  Google Scholar 

Cappell, K. M., & Kochenderfer, J. N. (2023). Long-term outcomes following CAR T cell therapy: What we know so far. Nature Reviews Clinical Oncology, 20(6), 359–371. https://doi.org/10.1038/s41571-023-00754-1

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chong, E. A., Ruella, M., Schuster, S. J., Lymphoma Program Investigators at the University of, P. (2021). Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. New England Journal of Medicine, 384(7), 673–674. https://doi.org/10.1056/NEJMc2030164

Article  PubMed  Google Scholar 

Morotti, M., Albukhari, A., Alsaadi, A., Artibani, M., Brenton, J. D., Curbishley, S. M., et al. (2021). Promises and challenges of adoptive T-cell therapies for solid tumours. British Journal of Cancer, 124(11), 1759–1776. https://doi.org/10.1038/s41416-021-01353-6

Article  PubMed  PubMed Central  Google Scholar 

June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. New England Journal of Medicine, 379(1), 64–73. https://doi.org/10.1056/NEJMra1706169

Article  PubMed  CAS  Google Scholar 

Labanieh, L., & Mackall, C. L. (2023). CAR immune cells: Design principles, resistance and the next generation. Nature, 614(7949), 635–648. https://doi.org/10.1038/s41586-023-05707-3

Article  PubMed  CAS  Google Scholar 

Majzner, R. G., & Mackall, C. L. (2019). Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine, 25(9), 1341–1355. https://doi.org/10.1038/s41591-019-0564-6

Article  PubMed  CAS  Google Scholar 

Sadelain, M., Riviere, I., & Riddell, S. (2017). Therapeutic T cell engineering. Nature, 545(7655), 423–431. https://doi.org/10.1038/nature22395

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020). Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 17(3), 147–167. https://doi.org/10.1038/s41571-019-0297-y

Article  PubMed  Google Scholar 

Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020). CAR T cell therapy for solid tumors: Bright future or dark reality? Molecular Therapy, 28(11), 2320–2339. https://doi.org/10.1016/j.ymthe.2020.09.015

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tantalo, D. G., Oliver, A. J., von Scheidt, B., Harrison, A. J., Mueller, S. N., Kershaw, M. H., et al. (2021). Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-002555

Article  PubMed  PubMed Central  Google Scholar 

Maher, J., & Davies, D. M. (2023). CAR-based immunotherapy of solid tumours-A survey of the emerging targets. Cancers (Basel). https://doi.org/10.3390/cancers15041171

Article  PubMed  PubMed Central  Google Scholar 

Gumber, D., & Wang, L. D. (2022). Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. eBioMedicine, 77, 103941. https://doi.org/10.1016/j.ebiom.2022.103941

Article  PubMed  PubMed Central  CAS  Google Scholar 

Del Bufalo, F., De Angelis, B., Caruana, I., Del Baldo, G., De Ioris, M. A., Serra, A., et al. (2023). GD2-CART01 for relapsed or refractory high-risk neuroblastoma. New England Journal of Medicine, 388(14), 1284–1295. https://doi.org/10.1056/NEJMoa2210859

Article  PubMed  Google Scholar 

Heczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., et al. (2017). CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Molecular Therapy, 25(9), 2214–2224. https://doi.org/10.1016/j.ymthe.2017.05.012

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kaczanowska, S., Murty, T., Alimadadi, A., Contreras, C. F., Duault, C., Subrahmanyam, P. B., et al. (2024). Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell, 42(1), 35–51. https://doi.org/10.1016/j.ccell.2023.11.011. e38.

Article  PubMed  CAS  Google Scholar 

Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., et al. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood, 118(23), 6050–6056. https://doi.org/10.1182/blood-2011-05-354449

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine, 14(11), 1264–1270. https://doi.org/10.1038/nm.1882

Article  PubMed  PubMed Central  CAS  Google Scholar 

Straathof, K., Flutter, B., Wallace, R., Jain, N., Loka, T., Depani, S., et al. (2020). Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abd6169

Article  PubMed  Google Scholar 

Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., et al. (2022). GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. https://doi.org/10.1038/s41586-022-04489-4

Article  PubMed  PubMed Central  Google Scholar 

Weber, E. W., Lynn, R. C., Sotillo, E., Lattin, J., Xu, P., & Mackall, C. L. (2019). Pharmacologic control of CAR-T cell function using dasatinib. Blood Advances, 3(5), 711–717. https://doi.org/10.1182/bloodadvances.2018028720

Article  PubMed  PubMed Central  CAS  Google Scholar 

Majzner, R. G., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., Yeom, K., et al. (2022). Abstract CT001: Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells. Cancer Research, 82(12_Supplement), CT001–CT001. https://doi.org/10.1158/1538-7445.Am2022-ct001

Article  Google Scholar 

Rooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixbey, J. W., Gan, Y., et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus–induced lymphoma in allogeneic transplant recipients. Blood, 92(5), 1549–1555. https://doi.org/10.1182/blood.V92.5.1549

Article  PubMed  CAS  Google Scholar 

Thomas, S., Straathof, K., Himoudi, N., Anderson, J., & Pule, M. (2016). An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers. PLoS One1, 11(3), e0152196.